Evidence map›Paper›PMID 36699085›Full record

ArticleFrontiers in pharmacology2022

Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia.

Evelien G E Hurkmans, Marije J Klumpers, Cinzia Dello Russo, Ward De Witte, Henk-Jan Guchelaar, Hans Gelderblom, Anne-Marie Cleton-Jansen, Sita H Vermeulen, Suzanne Kaal, Winette T A van der Graaf and 22 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 12 institutions in 4 countries.

Evelien G E HurkmansDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Marije J KlumpersDepartment of Pediatrics, Radboud University Medical Center, Nijmegen, Netherlands.
Cinzia Dello RussoDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United Kingdom.
Ward De WitteDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Henk-Jan GuchelaarDepartment of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands.
Hans GelderblomDepartment of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
Anne-Marie Cleton-JansenDepartment of Pathology, Leiden University Medical Center, Leiden, Netherlands.
Sita H VermeulenDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands.
Suzanne KaalDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
Winette T A van der GraafDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
Uta FluckeDepartment of Pathology, Radboud University Medical Center, Nijmegen, Netherlands.
Corrie E M GiddingPrincess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.
Hendrik W B SchreuderDepartment of Orthopedics, Radboud University Medical Center, Nijmegen, Netherlands.
Eveline S J M de BontDepartment of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, Netherlands.
Huib N CaronDepartment of Pediatrics, Amsterdam University Medical Centers, Emma Children's Hospital, Amsterdam, Netherlands.
Giovanna GattusoPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Elisabetta SchiavelloPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Monica TerenzianiPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Maura MassiminoPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Geoff McCowageCancer Centre for Children, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Sumanth NagabushanCancer Centre for Children, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Anuja LimayeDepartment of Audiology, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Victoria RoseDepartment of Neuro-Otology, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia.
Daniel CatchpooleChildren's Cancer Research Unit, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Andrea L JorgensenDepartment of Health Data Science, University of Liverpool, Liverpool, United Kingdom.
Christopher BartonDepartment of Women's and Children's Health, University of Liverpool, Liverpool, United Kingdom.
Lucy DelaneyDepartment of Women's and Children's Health, University of Liverpool, Liverpool, United Kingdom.
Daniel B HawcuttDepartment of Women's and Children's Health, University of Liverpool, Liverpool, United Kingdom.
Munir PirmohamedDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
Barry PizerDepartment of Pediatric Oncology, Alder Hey Children's Hospital, Liverpool, United Kingdom.
Marieke J H CoenenDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
D Maroeska W M Te LooDepartment of Pediatrics, Radboud University Medical Center, Nijmegen, Netherlands.
Radboud University Nijmegen · NLUniversity of Liverpool · GBChildren's Hospital at Westmead · AUFondazione IRCCS Istituto Nazionale dei Tumori · ITLeiden University Medical Center · NLRadboud University Medical Center · NLAlder Hey Children's Hospital · GBEmma Kinderziekenhuis · NLPrincess Máxima Center · NLThe Netherlands Cancer Institute · NLThe University of Sydney · AUUniversity Medical Center Groningen · NL

Funding

Medical Research Council MR/L006758/1
6 · The paper itself

Abstract

Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin chemotherapy. The aim of this study is to identify novel genetic variants that play a role in platinum-induced ototoxicity. Therefore, a genome-wide association study was performed in the Genetics of Childhood Cancer Treatment (GO-CAT) cohort (n = 261) and the United Kingdom Molecular Genetics of Adverse Drug Reactions in Children Study (United Kingdom MAGIC) cohort (n = 248). Results of both cohorts were combined in a meta-analysis. In primary analysis, patients with SIOP Boston Ototoxicity Scale grade ≥1 were considered cases, and patients with grade 0 were controls. Variants with a

Indexed as

carboplatinchildhood cancercisplatinGWASototoxicityTSPAN5

Identifiers

PMID36699085
PMCPMC9870026
OpenAlexW4313825660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.